KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K

What Happened

• On July 10, 2026 Kestra Medical Technologies, Ltd. and its subsidiary entered a five-year senior secured Loan Agreement providing up to $200.0 million in term loans split into four tranches. A committed Tranche A of $75.0 million was funded on July 10, 2026; net proceeds to the borrower from Tranche A were approximately $20.0 million after fees, costs and repayment of the prior loan. The loans mature July 10, 2031 and bear interest at 5.50% plus three‑month SOFR (SOFR floor 3.25%).
• On July 14, 2026 the company filed a press release reporting its financial results for the fiscal quarter ended April 30, 2026 (Exhibit 99.1 to the 8-K).

Key Details

• Facility size and structure: up to $200.0M total in four tranches — Tranche A $75M (funded), Tranche B $25M (borrower option through 7/31/2027), Tranche C $50M (available upon reaching $150M trailing‑12‑month revenue, requestable through 6/30/2028), Tranche D $50M (uncommitted for acquisitions subject to lender approval).
• Interest, term and payments: 5.50% + 3‑month SOFR (3.25% floor); 5‑year term maturing 7/10/2031; 48 months interest‑only then amortization in four equal quarterly payments starting Q2 2030; interest payable quarterly.
• Security and covenants: loan is senior secured with a security interest in substantially all assets (including IP); customary affirmative and restrictive covenants apply, and the borrower must maintain at least $20.0M in cash and cash equivalents.
• Use of proceeds: remaining proceeds after fees and prior loan repayment will be used for general corporate and working capital purposes.

Why It Matters

• The facility gives Kestra an expanded borrowing capacity and liquidity runway, with an immediate funded tranche but substantial conditions on drawing additional tranches (revenue targets and lender approvals).
• Because the loans are secured and include customary covenants and cash‑minimum requirements, they can limit flexibility for dividends, new debt or certain transactions unless waived.
• Retail investors should review the July 14, 2026 press release (filed as Exhibit 99.1) for the quarter’s revenue and earnings details and monitor whether Kestra hits the $150M TTM revenue threshold that would unlock Tranche C.